Simons F E, Persaud M P, Gillespie C A, Cheang M, Shuckett E P
Department of Pediatrics and Child Health, Faculty of Medicine, University of Manitoba, Canada.
Lancet. 1993 Sep 25;342(8874):776-8. doi: 10.1016/0140-6736(93)91541-s.
The prevalence of posterior subcapsular cataracts in young patients receiving inhaled glucocorticoids for treatment of chronic asthma is unknown. In a cross-sectional study, slit-lamp examinations were done on 95 consecutive young patients who were taking inhaled beclomethasone or budesonide. No posterior subcapsular cataracts were found. The median age of the patients was 13.8 (range 5.8-24.8). The median dose of inhaled beclomethasone or budesonide was 750 micrograms/day (range 300-2000), or 12.9 micrograms/kg per day (range 7.5-34.2). The median duration of treatment was 5 years (range 1-15). 77% of the patients had not used oral glucocorticoids in the year preceding the examination. This study suggests that routine screening for posterior subcapsular cataracts in this patient population is not warranted.
接受吸入性糖皮质激素治疗慢性哮喘的年轻患者后囊下白内障的患病率尚不清楚。在一项横断面研究中，对95例连续服用吸入性倍氯米松或布地奈德的年轻患者进行了裂隙灯检查。未发现后囊下白内障。患者的中位年龄为13.8岁（范围5.8 - 24.8岁）。吸入性倍氯米松或布地奈德的中位剂量为750微克/天（范围300 - 2000微克/天），或12.9微克/千克/天（范围7.5 - 34.2微克/千克/天）。中位治疗持续时间为5年（范围1 - 15年）。77%的患者在检查前一年未使用过口服糖皮质激素。这项研究表明，对该患者群体进行后囊下白内障的常规筛查没有必要。
